ARBOK-Lutetium (metal case)

Overview

There is no lutetium mine anywhere. Every kilogram is a by-product of rare earth separation. World output is ~10 t/yr of separated oxide at ~$707/kg. China holds 90–95% of heavy-group separation capacity, and in 2025 lutetium was placed under export licensing in all metal forms — never suspended, no expiry date.

The load on those ten tonnes is medical, and that is what makes this case different from the rest of the series. Lu-177 is the therapeutic isotope in radioligand treatment of metastatic prostate cancer and neuroendocrine tumours; revenue already exceeds $2 bn/yr with projections of $6–15 bn by the early 2030s. LSO/LYSO crystals are the detector in every PET scanner and have no substitute for time-of-flight. ~35% of oxide demand goes to FCC catalysts — that fraction is substitutable, the medical fraction is not.

The ratio has no parallel among the elements: raw oxide market $90–150 M worldwide; the market for articles made from it exceeds $5 bn. A licence over $150 M of feedstock is a licence over the world's radioligand oncology.

Position matters. Lutetium is the last element of the lanthanide row, the far end of the separation sequence, where a solvent-extraction cascade needs the most stages and where the incumbent monopoly is most secure. A route that does not require the cascade does not inherit that constraint.

> Core technology and architecture: see ARBOK-VC (Vacuum Cracking).

Applications

Feedstock streams: phosphogypsum, fresh and from stacks; acid mine drainage of coal and sulphide basins; monazite processing liquors; spent FCC catalysts.

Outputs: lutetium fraction (refining to isotope-production purity is a separate, uncosted step); Nd, Pr, Dy, Tb and the rest of the suite from the same pass; clean water; acid returned to process; radionuclides immobilised into a small residue fraction.

End uses: Lu-177 radiopharmaceuticals, LSO/LYSO scintillator crystals, FCC catalysts.

Operating Principle

Phosphogypsum is dissolved in the acid medium the process generates itself — no reagent purchased — and the stream is separated by cold boiling under deep vacuum. No furnaces, membranes, consumable reagents or CO2 from the recovery step. Separation of the rare earths happens in a single pass, inside the solution itself, without the classical cascade of hundreds of stages.

Key Parameters

Lutetium oxide: ~$707/kg bulk. World output ~10 t/yr separated oxide. Raw oxide market $90–150 M/yr worldwide.

China: 90–95% of heavy-group separation. Export licensing since 2025, all forms, no expiry.

Downstream: Lu-177 therapy revenue >$2 bn/yr, projected $6–15 bn by early 2030s; LSO/LYSO PET crystal market ~$0.75 bn (2022) to ~$1.5 bn (2030). Catalysts ~35% of oxide demand.

Phosphogypsum: ~3,500 mg/kg total REE, of which lutetium ~0.3 mg/kg (measured, Phalaborwa-type; not universal).

Florida: 30 M t/yr fresh phosphogypsum = ~9 t Lu/yr, comparable to entire Chinese annual separated output. Accumulated >1 bn t in ~25 stacks = ~300 t Lu = ~30 years of world production. ~$1.8 bn reserved for closure under the EPA settlement.

No recycling of lutetium anywhere.

Architecture and Components

Arbok-SA route: dissolution + deep-vacuum cold boiling + in-solution separation. Radionuclide immobilisation into a small residue fraction. Shared platform with ARBOK-Terbium, ARBOK-Lanthanum-Cerium, ARBOK-Dysprosium, ARBOK-Yttrium, ARBOK-PHOSPHOGYPSUM.

Advantages

Technical: reaches the far end of the lanthanide row without the cascade that makes that end expensive.

Economic: the lutetium line rides on a project whose economics rest on the full REE basket; acids and clean water of the same pass carry the process.

Strategic: converts a licensed single-jurisdiction dependency for a cancer therapy into recovery from a domestic liability already funded for closure.

Integrations

Phosphoric-acid plants and their stacks; mine water treatment under reclamation bonds; refinery catalyst regeneration. Connects to ARBOK-PHOSPHOGYPSUM, ARBOK-Terbium, ARBOK-Scandium-REE, ARBOK-Neodymium, ARBOK-SA.

Deployment & Operation

Assay of stack/rock and of drainage, with explicit Lu determination (it is at the detection tail and is routinely not reported) → configuration → install on the existing stream. Purchase or BOOM with off-take on the separated fractions.

TRL

Platform TRL 9; Arbok-SA route per the lanthanum/phosphogypsum case. Lutetium-specific field reference pending. Refining to isotope-production purity is materially above commercial oxide grade and is not demonstrated or costed in-house.

Market Potential

Not a tonnage market — a permission market. The buyer is a radiopharmaceutical manufacturer or a crystal grower whose constraint is an export licence with no expiry, not a price. Every phosphate site with a stack in a jurisdiction that wants domestic radioisotope supply is a candidate.

Typical Project Economics

Basis: phosphate site handling 1 Mt/yr of phosphogypsum.

• Lutetium contained: ~300 kg/yr = ~$212k/yr. Modest as revenue; 3% of world annual output from one waste pile is the number that matters.
• Ten comparable sites: ~3 t/yr = roughly one third of world supply.
• The same pass carries ~3,000 t/yr of contained REO — Nd, Pr, Dy, Tb and the rest — which is what actually funds the project.
• Water and acid returned rather than consumed.

Florida scale check: 30 Mt/yr fresh = ~9 t Lu/yr; >1 bn t accumulated = ~300 t Lu.

Risk Factors

Lu content varies with phosphate source and sits at the analytical tail — insist on explicit Lu determination, never infer it from TREO. The 0.3 mg/kg figure is a measured distribution, not a universal constant. Market is ~10 t/yr: material new supply cannot be absorbed at once and must be contracted, not stockpiled. Isotope-grade purity is far above commercial oxide grade and its cost is unknown to us. Radionuclide-residue acceptance and conservative phosphate-industry adoption remain as in the other phosphogypsum cases.

Related Technologies

ARBOK-Terbium · ARBOK-Dysprosium · ARBOK-Yttrium · ARBOK-Lanthanum-Cerium · ARBOK-PHOSPHOGYPSUM · ARBOK-SA · ARBOK-VC (Vacuum Cracking)